| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
40,660,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Werewolf Therapeutics is a biopharmaceutical company, engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Co. is utilizing its proprietary PREDATOR platform to design molecules that stimulate both adaptive and innate immunity with the aim of addressing the limitations of conventional proinflammatory immune therapies. Co.'s molecules, which it refers to as INDUKINE molecules, are intended to activate selectively in the tumor microenvironment. Co.'s product candidates, WTX-124 and WTX-330, are delivered, activated Interleukin-2 and Interleukin-12, respectively, INDUKINE molecules for the treatment of solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
536,426 |
536,426 |
536,426 |
536,426 |
| Total Buy Value |
$487,188 |
$487,188 |
$487,188 |
$487,188 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
3 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
8,774 |
8,774 |
8,774 |
| Total Sell Value |
$0 |
$9,212 |
$9,212 |
$9,212 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shah Rajeev M. |
Director |
– • • |
2025-05-14 |
4 |
B |
$0.98 |
$159,288 |
I/I |
162,539 |
6,237,482 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-05-13 |
4 |
B |
$0.98 |
$51,915 |
I/I |
52,974 |
6,074,943 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2025-05-12 |
4 |
B |
$0.86 |
$275,985 |
I/I |
320,913 |
6,021,969 |
2.25 |
- |
|
| Foley Todd |
10% Owner |
– – • |
2025-03-27 |
4 |
S |
$1.05 |
$2,061 |
I/I |
(1,963) |
3,208,793 |
|
- |
|
| Foley Todd |
10% Owner |
– – • |
2025-03-27 |
4 |
OE |
$0.09 |
$2,048 |
I/I |
22,758 |
3,210,756 |
|
- |
|
| Evnin Luke |
|
– • • |
2025-03-27 |
4 |
S |
$1.05 |
$2,546 |
I/I |
(2,425) |
4,309,860 |
|
- |
|
| Evnin Luke |
|
– • • |
2025-03-27 |
4 |
OE |
$0.09 |
$2,530 |
I/I |
28,113 |
4,312,285 |
|
- |
|
| Mpm Asset Management Llc |
10% Owner |
– – • |
2025-03-27 |
4 |
S |
$1.05 |
$4,605 |
I/I |
(4,386) |
6,718,670 |
|
- |
|
| Mpm Asset Management Llc |
10% Owner |
– – • |
2025-03-27 |
4 |
OE |
$0.09 |
$4,579 |
I/I |
50,873 |
6,723,056 |
|
- |
|
| Atkins Michael B. |
|
– • – |
2024-01-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,419 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2023-01-06 |
4 |
B |
$2.21 |
$4,095,130 |
I/I |
1,853,000 |
5,701,056 |
2.25 |
- |
|
| Seidel-Dugan Cynthia |
Chief Scientific Officer |
• – – |
2022-01-12 |
4 |
OE |
$1.56 |
$111,838 |
D/D |
39,731 |
164,888 |
|
- |
|
| Leonard Reid |
Chief Operating Officer |
• – – |
2021-12-30 |
4 |
OE |
$1.56 |
$21,999 |
D/D |
14,102 |
14,102 |
|
- |
|
| Leonard Reid |
Chief Operating Officer |
• – – |
2021-12-15 |
4 |
AS |
$13.39 |
$40,242 |
I/I |
(3,000) |
122,157 |
|
- |
|
| Evnin Luke |
Director |
– • • |
2021-05-04 |
4 |
B |
$16.00 |
$2,412,784 |
I/I |
150,799 |
4,284,172 |
2.25 |
- |
|
| Evnin Luke |
Director |
– • • |
2021-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
3,671,965 |
4,133,373 |
|
- |
|
| Mpm Asset Management Investors Bv2014 Llc |
10% Owner |
– – • |
2021-05-04 |
4 |
B |
$16.00 |
$2,012,144 |
I/I |
125,759 |
3,187,998 |
1.5 |
- |
|
| Mpm Asset Management Investors Bv2014 Llc |
10% Owner |
– – • |
2021-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
3,062,239 |
3,062,239 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2021-05-04 |
4 |
B |
$16.00 |
$27,440,000 |
I/I |
1,715,000 |
443,825 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2021-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
2,253,583 |
338,037 |
|
- |
|
| Mpm Oncology Impact Management Gp Llc |
10% Owner |
– – • |
2021-05-04 |
4 |
B |
$16.00 |
$3,920,000 |
I/I |
245,000 |
6,672,183 |
1.5 |
- |
|
| Mpm Oncology Impact Management Gp Llc |
10% Owner |
– – • |
2021-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
5,965,775 |
6,427,183 |
|
- |
|
| Hbm Bioventures Cayman Ltd |
10% Owner |
– – • |
2021-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
625,995 |
625,995 |
|
- |
|
| Lazarus Alon |
Director |
– • • |
2021-05-04 |
4 |
B |
$16.00 |
$6,400,000 |
I/I |
400,000 |
2,046,634 |
2.25 |
- |
|
| Lazarus Alon |
Director |
– • • |
2021-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
1,646,634 |
1,646,634 |
|
- |
|
44 Records found
|
|
Page 1 of 2 |
|
|
